Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Lek Pharmaceuticals D d
Lek Pharmaceuticals D d_20100121
Lek Pharmaceuticals D d_20100128
  

Lek Pharmaceuticals D d patents

Recent patent applications related to Lek Pharmaceuticals D d. Lek Pharmaceuticals D d is listed as an Agent/Assignee. Note: Lek Pharmaceuticals D d may have other listings under different names/spellings. We're not affiliated with Lek Pharmaceuticals D d, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "L" | Lek Pharmaceuticals D d-related inventors




Date Lek Pharmaceuticals D d patents (updated weekly) - BOOKMARK this page
09/14/17Spray-freeze drying of polyelectrolyte nanoparticles containing the protein drug
08/03/17Novel hydrates of dolutegravir sodium
06/22/17Processes for the preparation of beta-aminosulfone compounds
12/01/16Solid pharmaceutical compositions of androgen receptor antagonists
10/06/161-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
07/14/16Cell culture medium and process for controlling a-amidation and/or c-terminal amino acid cleavage of polypeptides
07/07/16Enzymatic route for the preparation of chiral gamma-aryl-beta-aminobutyric acid derivatives
05/26/16Novel crystalline hydrates of 1-(beta-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
05/12/16Coated particles and pharmaceutical dosage forms
03/03/16New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
07/09/15Ticagrelor adducts with divalent metal salts
05/28/15New synthetic route for the preparation of beta-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha]pyrazin-7-yl compounds
05/21/15Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
04/16/15Oxidative degradation products of atrovastatin calcium
03/19/15Reduction of formation of amidated amino acids in cell lines for protein expression
01/01/15Synthesis of triazolopyrimidine compounds
12/18/14Synthesis of triazolopyrimidine compounds
09/25/14Production of glycoproteins with low n-glycolylneuraminic acid (neu5gc) content
09/11/14Production of glycoproteins with low n-glycolylneuraminic acid (neu5gc) content
09/11/14Synthesis of triazolopyrimidine compounds
09/04/14Pharmaceutical composition comprising fesoterodine
07/31/14Preparation of sitagliptin intermediates
07/03/14Preparation of sitagliptin intermediates
05/15/14Pharmaceutical composition
05/15/14Synthesis of intermediates for preparing anacetrapib and derivatives thereof
03/27/14Method for controlling the main complex n-glycan structures and the acidic variants and variability in bioprocesses producing recombinant proteins
02/20/14Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof
02/13/14Pharmaceutical composition comprising a thiazolidinedione
12/19/13Enzymatic synthesis of active pharmaceutical ingredient and intermediates thereof
12/19/13Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
11/28/13Process for the preparation of 3-aroyl-5-aminobenzofuran derivatives
11/14/13Nuclear dna content of cho cell lines as a selection criterion in screening of the best recombinant protein producers
10/03/13Pharmaceutical compositions comprising glimepiride and polyethylene glycol castor oil
08/08/13Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt
08/01/13Short synthesis of tolterodine, intermediates and metabolites
05/09/13Coating of particles comprising a pharmaceutically active ingredient with a carbonate salt or phosphate salt
03/07/13Pharmaceutical compositions comprising a combination of metformin and sitagliptin
01/17/13Processes for the preparation of key intermediate for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
11/22/12Process for preparation of tacrolimus
09/13/12New synthetic route for the preparation of alpha-amino boronic acid derivatives via substituted alk-1-ynes
08/30/12Process for hydrogenation of halogenoalkenes without dehalogenation
08/02/12Synthesis of statins
06/14/12Process for dimethylation of active methylene groups
05/31/12Process for the preparation of a pharmaceutical composition comprising ezetimibe
04/12/12Pharmaceutical compositions of active pharmaceutical ingredient comprising sulphonylurea moiety with excellent dissolution properties
04/12/12Active pharmaceutical ingredient adsorbed on solid support
04/05/12Synthesis of 1-(2,3-dihydrobenzofuran-4-yl)ethanone as intermediate in the preparation of ramelteon
03/29/12Novel salts of sitagliptin
03/22/12Synthesis of (s)-n-[2-(1,6,7,8-tetrahydro-2h-indeno-[5,4-b]furan-8-yl)ethyl]propionamide
02/02/12Pharmaceutical composition comprising ezetimibe and simvastatin
02/02/12Controlled release pharmaceutical compositions comprising o-desmethyl-venlafaxine
01/26/12Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
12/15/11Mammalian expression vector
11/10/11New crystal form of sunitinib malate
10/27/11Novel ezetimibe formulations
10/27/11Process for the preparation or purification of olmesartan medoxomil
09/15/11Process for the preparation of olmesartan medoxomil
07/28/11Synthesis of 6,7-dihydro-1h-indeno[5, 4-b] furan-8(2h)-one as intermediate in the preparation of remelteon
07/28/11Process for the preparation of methyl ester of rosuvastatin
07/21/11Synthesis of statins
07/07/11New trinem antibiotics and inhibitors of beta-lactamases
06/09/11Granulation of active pharmaceutical ingredients
06/02/11Ezetimibe process and composition
05/12/11Self-microemulsifying systems incorporated into liquid core microcapsules
05/12/11Tablet comprising eprosartan mesylate
Patent Packs
05/05/112'-halobiphenyl-4-yl intermediates in the synthesis of angiotensin ii antagonists
04/28/11Catalyzed carbonylation in the synthesis of angiotensin ii antagonists
04/21/11Selenium containing modifying agents and conjugates
03/24/11Preparation of nanoparticles by using a vibrating nozzle device
02/24/11((2s,4r)-4,6-dihydroxytetrahydro-2h-pyran-2-yl)methyl carboxylate and process for the production thereof
02/10/11Controlled release tamsulosin hydrochloride tablets and a process of making them
01/27/11Method of preparing stabilized pharmaceutical compositions comprising active ingredients susceptible to conversion to alternate polymorph forms
01/13/11Duloxetin composition
12/30/10Self-microemulsifying drug delivery systems
12/02/10Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubility
11/25/10Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
09/16/10Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-n-alkyl-3-phenylpropylamines
09/02/10Oxidative degeneration products of atorvastatin calcium
07/22/10Gastroresistant pharmaceutical dosage form comprising n-(2-(2- phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
07/08/10Hot-melt micropellets
Patent Packs
05/13/10Process for preparing solid dosage forms of rosiglitazone maleate
04/08/10S-omeprazole magnesium
03/25/10Process for solvent removal from omeprazole salts
03/04/10Oxidative degradation products of atorvastatin calcium
02/25/10Pharmaceutical composition comprising perindopril
02/11/10Bursting pellets
01/28/10Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
01/21/10Process for the preparation of perindopril erbumine
01/21/10Process for the preparation of esomeprazole magnesium in a stable form
12/24/09Synthesis of 4-bromomethyl-2'-formylbiphenyl and 4-bromomethyl-2'-hydroxymethylbiphenyl and its use in preparation of giotensin ii antagonists
11/26/09Multiple unit tablets
10/22/09Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
09/24/09Pharmaceutical composition
09/17/09Novel process
09/03/09Crystalline solvate of omeprazole sodium
08/27/09Coated formulations for tolterodine
08/20/09Novel polymorph form of irbesartan
08/13/09Pharmaceutical composition
07/16/09Process for the preparation of amorphous calcium salt of atorvastatin
07/09/09Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives
04/30/09Process for preparing amorphous rosuvastatin calcium of impurities
04/09/09Pharmaceutical composition
01/28/10Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
01/21/10Process for the preparation of esomeprazole magnesium in a stable form







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Lek Pharmaceuticals D d in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Lek Pharmaceuticals D d with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';